Acepodia (6976) Stock Overview

Acepodia, Inc. operates as a clinical stage biotechnology company. The company engages in developing cell therapies with its unique antibody cell conjugation (ACC) platform technology to address gaps in cancer care. It links tumor targeting antibodies to its proprietary immune cells, such as gamma delta 2 T cells to create novel ACE therapies. The company was founded in 2017 and is headquartered in Grand Cayman, the Cayman Islands.